{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:10Z","timestamp":1788675430003,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,5]]},"DOI":"10.7759\/cureus.80074","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T10:36:44Z","timestamp":1741171004000},"source":"Crossref","is-referenced-by-count":1,"title":["Late-Onset Neutropenia Induced by Rituximab in Rheumatic Diseases: A Report of Two Cases of Severe Presentation and a Literature Review"],"prefix":"10.7759","author":[{"given":"Giulia Fernandes M","family":"Trevisani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Furtado V","family":"Bento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilton","family":"Salles Rosa Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith MR","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003, 22:7359-68. 10.1038\/sj.onc.1206939","journal-title":"Oncogene"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149667","article-title":"Secondary rituximab-associated versus primary immunodeficiencies: the enigmatic border","volume":"52","author":"Ottaviano G","year":"2022","unstructured":"Ottaviano G, Sgrulletti M, Moschese V. Secondary rituximab-associated versus primary immunodeficiencies: the enigmatic border. Eur J Immunol. 2022, 52:1572-80. 10.1002\/eji.202149667","journal-title":"Eur J Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/152174","article-title":"An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia","volume":"20","author":"Zhang X","year":"2024","unstructured":"Zhang X, Rao M, Xu G. An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia. Arch Med Sci. 2024, 20:494-505. 10.5114\/aoms\/152174","journal-title":"Arch Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.7.832","article-title":"Indications for rituximab use in an integrated health care delivery system","volume":"26","author":"Delate T","year":"2020","unstructured":"Delate T, Hansen ML, Gutierrez AC, Le KN. Indications for rituximab use in an integrated health care delivery system. J Manag Care Spec Pharm. 2020, 26:832-8. 10.18553\/jmcp.2020.26.7.832","journal-title":"J Manag Care Spec Pharm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl393","article-title":"A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study","volume":"18","author":"Nitta E","year":"2007","unstructured":"Nitta E, Izutsu K, Sato T, et al.. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol. 2007, 18:364-9. 10.1093\/annonc\/mdl393","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach O","year":"2010","unstructured":"Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore). 2010, 89:308-18. 10.1097\/MD.0b013e3181f2caef","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.04.007","article-title":"Rituximab for immunologic renal disease: what the nephrologist needs to know","volume":"16","author":"Kronbichler A","year":"2017","unstructured":"Kronbichler A, Windpessl M, Pieringer H, Jayne DR. Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev. 2017, 16:633-43. 10.1016\/j.autrev.2017.04.007","journal-title":"Autoimmun Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.11.62","article-title":"Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms","volume":"4","author":"Tesfa D","year":"2011","unstructured":"Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol. 2011, 4:619-25. 10.1586\/ehm.11.62","journal-title":"Expert Rev Hematol"},{"key":"ref9","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5. (2024). Accessed. November 16, 2024: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_60."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130526","article-title":"Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab","volume":"41","author":"Abdulkader R","year":"2014","unstructured":"Abdulkader R, Dharmapalaiah C, Rose G, Shand LM, Clunie GP, Watts RA. Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol. 2014, 41:858-61. 10.3899\/jrheum.130526","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1114","article-title":"Febrile neutropenia","volume":"3","author":"Patel K","year":"2017","unstructured":"Patel K, West HJ. Febrile neutropenia. JAMA Oncol. 2017, 3:1751. 10.1001\/jamaoncol.2017.1114","journal-title":"JAMA Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/20499361221138346","article-title":"Approach to fever in patients with neutropenia: a review of diagnosis and management","volume":"9","author":"Keck JM","year":"2022","unstructured":"Keck JM, Wingler MJ, Cretella DA, et al.. Approach to fever in patients with neutropenia: a review of diagnosis and management. Ther Adv Infect Dis. 2022, 9:10.1177\/20499361221138346","journal-title":"Ther Adv Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa D","year":"2011","unstructured":"Tesfa D, Ajeganova S, H\u00e4gglund H, Sander B, Fadeel B, Hafstr\u00f6m I, Palmblad J. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011, 63:2209-14. 10.1002\/art.30427","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.892541","article-title":"Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment","volume":"16","author":"Reitblat T","year":"2015","unstructured":"Reitblat T, Wechsler A, Reitblat O. Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment. Am J Case Rep. 2015, 16:211-4. 10.12659\/AJCR.892541","journal-title":"Am J Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000034","article-title":"Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry","volume":"1","author":"Salmon JH","year":"2015","unstructured":"Salmon JH, Cacoub P, Combe B, et al.. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015, 1:e000034. 10.1136\/rmdopen-2014-000034","journal-title":"RMD Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia\u2014a rheumatology case series and review of the literature","volume":"35","author":"Monaco WE","year":"2016","unstructured":"Monaco WE, Jones JD, Rigby WF. Rituximab associated late-onset neutropenia\u2014a rheumatology case series and review of the literature. Clin Rheumatol. 2016, 35:2457-62. 10.1007\/s10067-016-3313-y","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2016.1138318","article-title":"Late-onset neutropenia after rituximab in ANCA-associated vasculitis","volume":"45","author":"Knight A","year":"2016","unstructured":"Knight A, Sundstr\u00f6m Y, B\u00f6rjesson O, Bruchfeld A, Malmstr\u00f6m V, Gunnarsson I. Late-onset neutropenia after rituximab in ANCA-associated vasculitis. Scand J Rheumatol. 2016, 45:404-7. 10.3109\/03009742.2016.1138318","journal-title":"Scand J Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318777116","article-title":"Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL","volume":"27","author":"Parodis I","year":"2018","unstructured":"Parodis I, S\u00f6der F, Faustini F, et al.. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL. Lupus. 2018, 27:1470-8. 10.1177\/0961203318777116","journal-title":"Lupus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.41501","article-title":"Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease","volume":"73","author":"Zonozi R","year":"2021","unstructured":"Zonozi R, Wallace ZS, Laliberte K, et al.. Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease. Arthritis Rheumatol. 2021, 73:347-54. 10.1002\/art.41501","journal-title":"Arthritis Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3357-23","article-title":"Late-onset neutropenia after rituximab treatment for MPO-ANCA-associated vasculitis","volume":"64","author":"Watanabe K","year":"2025","unstructured":"Watanabe K, Shimada N, Kanzaki M, Fukuoka K, Asano K. Late-onset neutropenia after rituximab treatment for MPO-ANCA-associated vasculitis. Intern Med. 2025, 64:581-4. 10.2169\/internalmedicine.3357-23","journal-title":"Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson JI","year":"2022","unstructured":"Robinson JI, Md Yusof MY, Davies V, et al.. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity. EBioMedicine. 2022, 86:104343. 10.1016\/j.ebiom.2022.104343","journal-title":"EBioMedicine"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02610-7","article-title":"Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy","author":"Tashiro Y","year":"2025","unstructured":"Tashiro Y, Hyodo Y, Kitamura S, et al.. Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy. Clin Exp Nephrol. 2025, 10.1007\/s10157-024-02610-7","journal-title":"Clin Exp Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105400","article-title":"Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis","volume":"82","author":"Baker D","year":"2024","unstructured":"Baker D, Kang AS, Giovannoni G, Schmierer K. Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis. Mult Scler Relat Disord. 2024, 82:105400. 10.1016\/j.msard.2023.105400","journal-title":"Mult Scler Relat Disord"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25751","article-title":"Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases","volume":"95","author":"Malpica Castillo LE","year":"2020","unstructured":"Malpica Castillo LE, Palmer S, Zhu A, Deal AM, Chen SL, Moll S. Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases. Am J Hematol. 2020, 95:E117-20. 10.1002\/ajh.25751","journal-title":"Am J Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/343571-late-onset-neutropenia-induced-by-rituximab-in-rheumatic-diseases-a-report-of-two-cases-of-severe-presentation-and-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T10:36:47Z","timestamp":1741171007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/343571-late-onset-neutropenia-induced-by-rituximab-in-rheumatic-diseases-a-report-of-two-cases-of-severe-presentation-and-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.80074","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,5]]}}}